Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy ...

while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy ...

Shares of Altimmune (NASDAQ:ALT) rallied 30% in afternoon trading after the company issued several business updates along ...

Meanwhile, Leerink Partners maintained their Outperform rating for Keros Therapeutics, citing the potential of another drug, cibotercept, to differentiate itself from competing treatments.

Highmark Health, Alignment Health and Network Health are on an exclusive list of Medicare Advantage carriers with five-star ...

The high-profile Asia-Pacific Economic Cooperation summit in Lima has thrust one of the world’s least popular presidents into ...